encephalitis.
CNM-Au8 Displays Positive Interim Results in Multiple Sclerosis
February 28, 2021
Clene Nanomedicine’s nanocatalyst agent CNM-Au8 displayed significant improvements in patients with EDSS scores of 2.0 or higher compared to those with EDSS scores of 1.5 or lower.
Early DMT Prescription in Radiologically Isolated Syndrome: Ilena George, MD
February 28, 2021
The neurologist from Massachusetts General Hospital gave an overview of her study presented at ACTRIMS.
Increasing Prevalence of Early DMT Prescription in Radiologically Isolated Syndrome
February 27, 2021
Researchers from Massachusetts General Hospital found that DMT-treated patients were, on average, younger than untreated patients.
MS Diagnosis Disclosure and Concealment Associated With Anxiety, Depression
February 27, 2021
Higher concealment behavior for patients with multiple sclerosis was associated with higher anxiety, but not depression.
Fingolimod Shows Potential to Reduce Retinal Neurodegeneration in Relapsing MS
February 27, 2021
The authors concluded that longitudinal optical coherence tomography measures may be sensitive to changes in cognitive function and may be useful for monitoring neuroprotective therapies.
Natalizumab Infusion Reports Strong Safety Profile, Rarely Causes Adverse Events in Relapsing MS
February 27, 2021
Researchers from the University of Washington Medical Center analyzed data from almost 10,000 infusions of natalizumab.
Social Activity Participation Impacted by Invisible Symptoms of MS
February 26, 2021
Data from a pair of posters suggest that cognition, fatigue, and depression all impact social activity limitations in people with MS, rather than walking impairment alone.
Instrumented Postural Sway Test Differentiates Fallers From Non-Fallers in MS
February 26, 2021
Researchers investigated the test, which is normally used to differentiate people with MS from healthy controls, in a population of those with multiple sclerosis.
Investigating TNFα Inhibition and CNS Demyelination: Spencer Hutto, MD
February 26, 2021
The fellow of autoimmune neurology at Massachusetts General Hospital discussed the analysis his team conducted to clarify the known associations.
New Studies Evaluating Anakinra and Tolebrutinib on Paramagnetic Rim Lesions in MS
February 26, 2021
The trial of anakinra is underway, while the trial for tolebrutinib is undergoing regulatory review.
Frenkel Coordination Exercises Demonstrate Reliability, Fatigue Benefits in Multiple Sclerosis
February 25, 2021
The authors concluded that this approach may be applied in fatigue management treatment protocols, without increasing symptoms, in patients with multiple sclerosis.
Growing Multiple Sclerosis Treatment Knowledge: Luc Truyen, MD, PhD
February 25, 2021
The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical detailed the areas research has grown in MS and areas that still need more examination.
Cladribine Demonstrates CD19+ B and CD4+ T Lymphocyte Impact Regardless of Age
February 25, 2021
The effect of cladribine on CD8+ T lymphocytes varied by age, with steady increases shown in the younger population whereas there were fluctuations observed in the older group.
Measuring MS Fatigue in a Real-World Setting: Allitia DiBernardo, MD
February 25, 2021
The global head of medical affairs-neurology at Janssen Pharmaceutical discussed 2 studies presented at the ACTRIMS Forum 2021 involving fatigue among patients with multiple sclerosis.
TNFαi-Associated CNS Demyelination Persists After Treatment Discontinuation
February 25, 2021
Researchers retrospectively analyzed patient follow-ups and found that 50% of patients were ultimately diagnosed with multiple sclerosis.